<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618564</url>
  </required_header>
  <id_info>
    <org_study_id>DMED#1845-15</org_study_id>
    <nct_id>NCT02618564</nct_id>
  </id_info>
  <brief_title>The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing</brief_title>
  <official_title>The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate sennosides as an adjunct to sodium picosulfate
      magnesium citrate (Pico Salax) in preparation for colonoscopy. We will compare different
      doses and administration times. The primary outcome is number of bowel motions produced.
      Secondary outcomes include the quality of bowel cleansing and patient tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will compare different doses and administration times in patients booked for morning
      colonoscopy. The primary outcome is number of bowel motions produced in total by the
      sennosides. Secondary outcomes include the quality of bowel cleansing and patient
      tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel movements, as measured by patient diary</measure>
    <time_frame>2 days</time_frame>
    <description>The primary outcome of this pilot study is the number of bowel movements. Patients will record the timing and number of bowel motions produced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colon cleansing, as measured by The Ottawa Scale and Aronchick Bowel Cleansing Scale</measure>
    <time_frame>2 days</time_frame>
    <description>The secondary outcome is colon cleansing efficacy. The endoscopist will grade the cleansing quality of the colon using two standardized measures - the Ottawa Scale and the 5-point Aronchick Bowel Preparation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability, as measured by patient questionnaire</measure>
    <time_frame>2 days</time_frame>
    <description>The secondary outcome is patient tolerability. Patients will be asked to complete a questionnaire examining symptoms such as nausea, bloating, vomiting, and abdominal pain.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Colonoscopy Preparation Outcome</condition>
  <arm_group>
    <arm_group_label>2 TABS QHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sennosides 2 tabs, taken two nights before the colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 TABS QHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sennosides 3 tabs, taken two nights before the colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 TABS AM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sennosides 2 tabs, taken the morning before the colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 TABS AM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sennosides 3 tabs, taken the morning before the colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 TABS AM &amp; QHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sennosides</intervention_name>
    <description>Each group will be assigned different doses of sennosides and varying times of administration</description>
    <arm_group_label>2 TABS QHS</arm_group_label>
    <arm_group_label>3 TABS QHS</arm_group_label>
    <arm_group_label>2 TABS AM</arm_group_label>
    <arm_group_label>3 TABS AM</arm_group_label>
    <arm_group_label>2 TABS AM &amp; QHS</arm_group_label>
    <other_name>Senokot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female patients 18 to 75 years of age inclusive

          -  Patients who require an outpatient colonoscopy with a split dose Pico-Salax prep

        Exclusion Criteria:

          -  Colonoscopy requiring the use of a large volume prep (eg Colyte, PEG)

          -  Ileus or bowel obstruction

          -  Previous colorectal surgery

          -  Ascites

          -  Recognized renal impairment (defined as GFR less than normal in 3 months prior to
             enrolment)

          -  Pregnancy

          -  Recent (&lt;6 months) myocardial infarction or unstable angina.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Hookey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Lawrence Hookey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Senna Extract</mesh_term>
    <mesh_term>Sennoside A&amp;B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

